Christopher Paul Cannon, MD
November 23rd, 2010
How Should We DEFINE Anacetrapib’s Success?
Philip John Barter, MD, PhD and Christopher Paul Cannon, MD
CardioExchange welcomes Philip Barter and Christopher P. Cannon, two of the investigators for the DEFINE trial, which was recently published in the New England Journal of Medicine. Here, they answer questions posed by CardioExchange’s editors. First, some background about the trial: In DEFINE, 1623 patients with or at high risk for coronary disease were randomized to receive […]
February 19th, 2010
Who Does and Who Doesn’t Get Aspirin? Can We Do Better?
Christopher Paul Cannon, MD
Aspirin is the best known and most widely used preventive therapy. A century of clinical experience and randomized trials in over 250,000 patients have proved its benefit in preventing cardiovascular events, and it costs pennies a day. So how can it be that not everyone who needs it gets it? In a new report, we used […]
NEJM Journal Watch — Recent Cardiology Articles- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?